HAMMERSMITH MEDICINES RESEARCH LIMITED
Get an alert when HAMMERSMITH MEDICINES RESEARCH LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£2.3M
Latest balance sheet
Net assets
£16M
lowest in 5 filed years
Employees
285
Average over period
Profit before tax
-£2.1M
Period ending 2025-07-31
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
1 PSC ceased in last 24 months
Significant control changed hands — see the Ownership section.
Net assets
5-year trend · vs Industrials median
Accounts
5-year trend · Δ = latest vs prior filed period · latest reflected 2025-07-31
| Metric | Trend | 2021-01-31 | 2022-01-31 | 2023-01-31 | 2024-01-31 | 2025-07-31 | Δ vs prior |
|---|---|---|---|---|---|---|---|
| Turnover | — | — | £20,614,693 | £21,477,373 | £24,671,858 | — | |
| Operating profit | — | — | -£2,048,908 | -£1,095,393 | -£2,276,243 | — | |
| Profit before tax | — | — | -£2,089,927 | -£1,027,864 | -£2,122,627 | — | |
| Net profit | — | — | -£1,396,931 | -£729,203 | -£1,091,049 | — | |
| Cash | £5,980,578 | £4,804,980 | £1,985,589 | £3,735,190 | £2,344,753 | — | |
| Total assets less current liabilities | £27,284,848 | £28,210,238 | £26,434,610 | £25,573,136 | £16,759,263 | — | |
| Net assets | £25,142,067 | £25,726,238 | £24,394,700 | £23,665,497 | £16,196,502 | — | |
| Equity | £25,142,067 | £25,726,238 | £24,394,700 | £23,665,497 | £16,196,502 | — | |
| Average employees | 265 | 291 | 308 | 291 | 285 | — | |
| Wages | — | — | £11,479,669 | £11,563,952 | £16,837,914 | — | |
| Directors' remuneration | — | — | £70,912 | £121,863 | £228,916 | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. Year-on-year comparison hidden: this filing covers about 18 months versus 12 months prior. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2021-01-31 | 2022-01-31 | 2023-01-31 | 2024-01-31 | 2025-07-31 |
|---|---|---|---|---|---|---|
| Operating margin | — | — | -9.9% | -5.1% | -9.2% | |
| Net margin | — | — | -6.8% | -3.4% | -4.4% | |
| Return on capital employed | — | — | -7.8% | -4.3% | -13.6% | |
| Current ratio | — | — | 6.25x | — | — |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- HAMMERSMITH MEDICINES RESEARCH LIMITED 1995-02-06 → present
- HAMMERSMITH MEDICAL RESEARCH LIMITED 1993-01-15 → 1995-02-06
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- S&W Audit
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the Directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”
Significant events
- “On 1 August 2025, NN Bidco Pty Ltd (as part of the "Nucleus Network" group) completed the acquisition of Hammersmith Medicines Research Limited (HMR).”
- “On 1 August 2025, the sale of 100% of the shares in the company to NN Bidco Pty Ltd (ACN 623 536 247), an Australian proprietary limited company, was completed. As a consequence of the sale, Dr M J Boyce and Dr S J Warrington resigned as directors and Ms T J Pisarev and Dr G K Wood were appointed as directors on the same date. The shares in the subsidiaries, Trio Medicines Limited and Hammersmith Medicines Research (Properties) Limited, together with intercompany balances, were transferred to the former ultimate controlling party, Dr M J Boyce, in advance of the above sale.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 6 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| PISAREV, Teena Joy | Director | 2025-08-01 | Sep 1974 | Australian |
| WOOD, Graham Keith | Director | 2025-08-01 | May 1972 | Canadian |
Show 6 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| O'BRIEN, Charles Kevin | Secretary | 1995-01-15 | 2025-01-31 |
| APPLETON SECRETARIES LIMITED | Corporate Nominee Secretary | 1993-01-15 | 1995-01-15 |
| BOYCE, Malcolm James, Dr | Director | 1993-01-18 | 2025-08-01 |
| SMITH, Russell, Professor | Director | 2012-08-07 | 2013-10-18 |
| WARRINGTON, Steven John, Dr | Director | 1996-01-26 | 2025-08-01 |
| APPLETON DIRECTORS LIMITED | Corporate Nominee Director | 1993-01-15 | 1993-01-18 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Nn Bidco Pty Ltd (Acn 623 536 247) | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2025-08-01 | Active |
| Dr Malcolm James Boyce | Individual | Shares 75–100% | 2016-04-06 | Ceased 2025-08-01 |
Filing timeline
Last 20 of 92 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-06-04 | AA | accounts | Accounts with accounts type full | |
| 2026-04-08 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-10-28 | AA01 | accounts | Change account reference date company previous extended | |
| 2025-08-06 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2025-08-06 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2025-08-06 | TM01 | officers | Termination director company with name termination date | |
| 2025-08-06 | TM01 | officers | Termination director company with name termination date | |
| 2025-08-06 | AP01 | officers | Appoint person director company with name date | |
| 2025-08-06 | AP01 | officers | Appoint person director company with name date | |
| 2025-05-21 | AA | accounts | Accounts with accounts type group | |
| 2025-01-31 | TM02 | officers | Termination secretary company with name termination date | |
| 2025-01-17 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-04-24 | AA | accounts | Accounts with accounts type group | |
| 2024-01-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-04-25 | AA | accounts | Accounts with accounts type group | |
| 2023-04-12 | DISS40 | gazette | Gazette filings brought up to date | |
| 2023-04-04 | GAZ1 | gazette | Gazette notice compulsory | |
| 2023-01-25 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-02-01 | AA | accounts | Accounts with accounts type group | |
| 2022-01-17 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 9
- Capital events
- 0
- Officers appointed
- 2
- Officers resigned
- 2
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.